KA
CRL icon

Kerrisdale Advisers’s Charles River Laboratories CRL Stock Holding History

Kerrisdale Advisers’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,043
Closed -$525K – 117
2026
Q1 		$525K Sell
3,043
-1,550
-34% -$287K 0.2% 85
2025
Q4 		$916K Sell
4,593
-2,865
-38% -$520K 0.43% 46
2025
Q3 		$1.17M Hold
7,458
– – 0.61% 40
2025
Q2 		$1.13M Sell
7,458
-2,606
-26% -$348K 0.59% 35
2025
Q1 		$1.51M Buy
10,064
+1,399
+16% +$235K 0.63% 32
2024
Q4 		$1.6M Buy
8,665
+2,160
+33% +$416K 0.54% 40
2024
Q3 		$1.28M Sell
6,505
-3,275
-33% -$681K 0.44% 52
2024
Q2 		$2.02M Sell
9,780
-1,225
-11% -$278K 0.63% 41
2024
Q1 		$2.98M Sell
11,005
-14,118
-56% -$3.37M 0.94% 32
2023
Q4 		$5.94M Buy
25,123
+3,627
+17% +$713K 1.77% 20
2023
Q3 		$4.21M Buy
21,496
+16,952
+373% +$3.48M 1.33% 25
2023
Q2 		$955K Buy
+4,544
New +$904K 0.26% 66
2022
Q3 		– Sell
-7,450
Closed -$1.59M – 80
2022
Q2 		$1.59M Sell
7,450
-6,536
-47% -$1.6M 0.5% 49
2022
Q1 		$3.97M Sell
13,986
-60,281
-81% -$18.6M 1.21% 21
2021
Q4 		$28M Buy
74,267
+39,752
+115% +$15.4M 5.78% 7
2021
Q3 		$14.2M Sell
34,515
-23,939
-41% -$9.94M 1.54% 27
2021
Q2 		$21.6M Sell
58,454
-64,691
-53% -$21.6M 1.94% 24
2021
Q1 		$35.7M Sell
123,145
-56,503
-31% -$15.7M 2.74% 14
2020
Q4 		$44.9M Sell
179,648
-44,189
-20% -$10.5M 3.48% 9
2020
Q3 		$50.7M Sell
223,837
-28,754
-11% -$5.97M 3.8% 3
2020
Q2 		$44M Buy
252,591
+3,295
+1% +$526K 4.95% 3
2020
Q1 		$31.5M Buy
249,296
+110,796
+80% +$16.6M 6.02% 3
2019
Q4 		$21.2M Buy
+138,500
New +$19.2M 7.48% 4

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Kerrisdale Advisers's CRL Position: Q2 2026 in Review

Kerrisdale Advisers sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 3,043 shares — an estimated $525K sold.

Kerrisdale Advisers first reported a position in CRL in Q4 2019 and held it in 23 quarters. The position peaked at $50.7M in Q3 2020. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Kerrisdale Advisers reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Kerrisdale Advisers sold 3,043 Charles River Laboratories shares in Q2 2026, an estimated $525K.
  • Kerrisdale Advisers first reported a position in Charles River Laboratories in Q4 2019 and held it in 23 quarters.
  • Kerrisdale Advisers's Charles River Laboratories position peaked at $50.7M in Q3 2020.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Kerrisdale Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.